GPR39 PET Imaging Agent: Synthesis and Preclinical Assessment Data

Bhuvanachandra Bhoopal published a dataset on figshare in March 2026 detailing the synthesis and preclinical evaluation of the first GPR39 PET imaging agent, [¹¹C]TMN-OMe. The dataset likely contains results from radiolabeling, microPET/CT imaging, biodistribution, and autoradiography analyses. These findings support using the radiotracer to quantify GPR39 levels in vivo for studying neurological disorders.

Use Cases

• Validate radiotracer synthesis protocols based on reported radiochemical purity and molar activity.
• Analyze in vivo binding selectivity based on microPET/CT imaging and autoradiography results.
• Compare GPR39 expression levels in disease models based on data from Alzheimer's disease and knockout mice.
• Assess radiotracer stability for clinical translation based on human serum stability tests.

Strengths

• Dataset is associated with a published study reporting the first radiotracer for GPR39 imaging.
• Preclinical evaluation includes multiple validation methods: microPET/CT, biodistribution, and autoradiography.
• Results include comparative data from GPR39 knockout mice, Alzheimer's disease mice, and blockade conditions.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset size is 668.0 B, indicating a very limited scope of data.

Provenance

Source

figshare

Freshness

Last updated 2026-03-19 05:45:19; freshness should be verified.